Asset Details

MbrlCatalogueTitleDetail

Do you wish to reserve the book?

FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer

by Volet, Julien , Artru, Pascal , Faroux, Roger , Choné, Laurence , Malka, David , Rat, Patrick , Khemissa-Akouz, Faiza , Bouhier-Leporrier, Karine , Hammel, Pascal , Biagi, James J , Assenat, Eric , Conroy, Thierry , Hebbar, Mohamed , Legoux, Jean-Louis , O’Callaghan, Christopher J , Breysacher, Gilles , Gourgou, Sophie , Ben Abdelghani, Meher , Jouffroy-Zeller, Claire , Kavan, Petr , Lecomte, Thierry , Wei, Alice C , Francois, Eric , Texereau, Patrick , Juzyna, Béata , Raoul, Jean-Luc , Castan, Florence , Di Fiore, Frédéric , Ychou, Marc , Cripps, Christine , Bachet, Jean-Baptiste , Sauvanet, Alain

in 5-Fluorouracil / Adenocarcinoma / Adjuvant therapy / Adjuvants / Adult / Aged / Aged, 80 and over / Antineoplastic Combined Chemotherapy Protocols - therapeutic use / Cancer / Cancer therapies / Cardiovascular disease / Chemotherapy / Chemotherapy, Adjuvant / Deoxycytidine - adverse effects / Deoxycytidine - analogs & derivatives / Deoxycytidine - therapeutic use / Disease-Free Survival / Drug Combinations / Fees & charges / Female / Fluorouracil - adverse effects / Fluorouracil - therapeutic use / Gemcitabine / Grants / Human health and pathology / Humans / Irinotecan / Leucovorin - adverse effects / Leucovorin - therapeutic use / Life Sciences / Lung Diseases, Interstitial - chemically induced / Male / Medical prognosis / Metastases / Metastasis / Middle Aged / NMR / Nuclear magnetic resonance / Organometallic Compounds - adverse effects / Organometallic Compounds - therapeutic use / Oxaliplatin / Pancreatic cancer / Pancreatic Neoplasms - drug therapy / Pneumonitis / Proportional Hazards Models / Prospective Studies / Safety / Survival

2018

Yes Please

Hey, we have placed the reservation for you!

By the way, why not check out events that you can attend while you pick your title.

Oops! Something went wrong.

Looks like we were not able to place the reservation. Kindly try again later.

Are you sure you want to remove the book from the shelf?

FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer

2018

Confirm

Do you wish to request the book?

FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer

2018

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy

How would you like to get it?

Submit

We have requested the book for you!

Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.

Oops! Something went wrong.

Looks like we were not able to place your request. Kindly try again later.

Journal Article

FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer

Volet, Julien,

Artru, Pascal,

Faroux, Roger,

Choné, Laurence,

Malka, David,

Rat, Patrick,

Khemissa-Akouz, Faiza,

Bouhier-Leporrier, Karine,

Hammel, Pascal,

Biagi, James J,

Assenat, Eric,

Conroy, Thierry,

Hebbar, Mohamed,

Legoux, Jean-Louis,

O’Callaghan, Christopher J,

Breysacher, Gilles,

Gourgou, Sophie,

Ben Abdelghani, Meher,

Jouffroy-Zeller, Claire,

Kavan, Petr,

Lecomte, Thierry,

Wei, Alice C,

Francois, Eric,

Texereau, Patrick,

Juzyna, Béata,

Raoul, Jean-Luc,

Castan, Florence,

Di Fiore, Frédéric,

Ychou, Marc,

Cripps, Christine,

Bachet, Jean-Baptiste,

Sauvanet, Alain

2018

Overview

In a prospective, randomized trial involving patients with resected pancreatic cancer, adjuvant combination chemotherapy with FOLFIRINOX resulted in a median disease-free survival of 21.6 months, as compared with 12.8 months with gemcitabine therapy. Overall survival was also longer with FOLFIRINOX.

Share this book

Add to My Shelf

Publisher

Massachusetts Medical Society

Subject

/ Adult

/ Aged

/ Aged, 80 and over